**Name of Journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 30234**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

Proteomic profiling of fetal esophageal epithelium, esophageal cancer, and tumor-adjacent esophageal epithelium and immunohistochemical characterization of a representative differential protein, PRX6

Jun-Hui Guo *et al.* Proteomic profiling of fetal esophagus, ESCC, NOR and IHC characterization of a representative differential protein, PRX6

Jun-Hui Guo, Guo-Lan Xing, Xin-Hui Fang, Hui-Fang Wu, Bo Zhang, Jin-Zhong Yu, Zong-Min Fan, Li-Dong Wang

**Jun-Hui Guo, Bo Zhang, Jin-Zhong Yu,** The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China

**Guo-Lan Xing, Zong-Min Fan, Li-Dong Wang,** Henan Key Lab For Esophageal Cancer Res, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

**Xin-Hui Fang,** Henan Province People’s Hospital, Zhengzhou 450003, Henan Province, China

**Hui-Fang Wu,** the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China

**Author contributions:** Guo JH designed and performed the research and wrote the paper; Wang LD designed the research and supervised the report; Xing GL designed the research and contributed to the analysis; Fang XH and Wu HF provided clinical advice; Zhang B, Yu JZ and Fan ZM supervised the research.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of The Second Affiliated Hospital of Henan University of Chinese Medicine.

**Informed consent statement:** Fetal esophagus was obtained from Huixian and Huojia Family Planning Centers. Adult esophagus were obtained from Linzhou Central Hospital and Yaocun Esophageal Tumor Hospital of Henan Province.For full disclosure, the details of the study are published on the Journal of Zhengzhou University.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Li-Dong Wang, Professor,** Henan Key Lab For Esophageal Cancer Res, The First Affiliated Hospital of Zhengzhou University, No. 40 Daxue Road, Zhengzhou 450052, Henan Province, China. ldwang2007@126.com

**Telephone**: +86-371-66658335

**Fax**: +86-371-66658335

**Received:** September 20, 2016

**Peer-review started:** September 22, 2016

**First decision:** October 20, 2016

**Revised:** November 3, 2016

**Accepted:** December 8, 2016

**Article in press:**

**Published online:**

# Abstract

***AIM***

To improve the understanding of the molecular mechanism of esophageal cancer development and provide molecular markers for screening populations at high risk for esophageal cancer and early diagnosis of this malignancy.

***METHODS***

Two-dimensional electrophoresis combined with mass spectrometry were adopted to screen differentially expressed proteins in nine cases of fetal esophageal epithelium, eight cases of esophageal cancer, and eight cases of tumor-adjacent normal esophageal epithelium collected from fetuses of different gestational age or esophageal cancer patients from a high risk area of esophageal cancer in China. Immunohistochemistry (avidin-biotin-horseradish peroxidase complex method) was used to detect the expression of peroxiredoxin 6 (PRX6) in 91 cases of esophageal cancer, tumor-adjacent normal esophageal tissue, basal cell hyperplasia, dysplasia, and carcinoma in situ as well as 65 cases of esophageal epithelium from fetuses at a gestational age of 3-9 mo.

***RESULTS***

After peptide mass fingerprint analysis and search of protein databases, a total of 21 differential proteins were identified, of which some represent a protein isoform. Varying degrees of expression of PRX6 protein, which was localized mainly in the cytoplasm, were detected in adult and fetal normal esophageal tissues, precancerous lesions, and esophageal cancer. With the progression of esophageal lesions, PRX6 protein expression showed a declining trend (*P* < 0.05). In fetal epithelium from fetuses at a gestational age of 3-6 mo, PRX6 protein expression showed a declining trend with age (*P* < 0.05). PRX6 protein expression was significantly higher in well differentiated esophageal cancer tissues than in poorly differentiated esophageal cancer tissues (*P* < 0.05).

***CONCLUSION***

Our results suggest that the development and progression of esophageal cancer are a result of interactions of many genetic changes (accumulation or superposition). PRX6 protein, one of differential proteins identified, is associated with fetal esophageal development and esophageal cancer differentiation.

**Key words:** Fetal esophageal epithelium; Esophageal squamous cell carcinoma; Tumor-adjacent esophageal epithelium; Proteomics

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This is a retrospective study to identify 21 significantly differentially expressed proteins that may be related to the development and growth of fetal esophageal epithelium or the development and progression of esophageal cancer, PRX6 protein,one of them,which was localized mainly in the cytoplasm, were detected in adult and fetal normal esophageal tissues, precancerous lesions, and esophageal cancer. With the progression of esophageal lesions, PRX6 protein expression showed a declining trend (*P* < 0.05). In fetal epithelium from fetuses at a gestational age of 3-6 mo, PRX6 protein expression showed a declining trend with age (*P* < 0.05). PRX6 protein expression was significantly higher in well differentiated esophageal cancer tissues than in poorly differentiated esophageal cancer tissues (*P* < 0.05). PRX6 protein, one of differential proteins identified, is associated with fetal esophageal development and esophageal cancer differentiation.

Guo JH, Xing GL, Fang XH, Wu HF, Zhang B, Yu J, Fan ZM, Wang LD. Proteomic profiling of fetal esophageal epithelium, esophageal cancer, and tumor-adjacent esophageal epithelium and immunohistochemical characterization of a representative differential protein, PRX6. *World J Gastroenterol* 2016; In press

# INTRODUCTION

Esophageal cancer is one of the most common thoracic malignancies that pose a serious threat to human health. There are about 400000 newly diagnosed cases of esophageal cancer and about 300000 cases of esophageal cancer related death worldwide each year, with the majority of patients diagnosed in developing countries. China is one of the countries or regions with high incidence and mortality rates of esophageal cancer. Since the 1990s, the overall incidence and mortality rates of esophageal cancer have declined in China; however, esophageal cancer is still the leading cause of cancer related death in northern Henan Province and Chaoshan area of Guangdong Province, both of which are high risk areas of esophageal cancer in China. Squamous cell carcinoma is the most important histological subtype of esophageal cancer in China. Esophageal cancer, especially esophageal squamous cell carcinoma, is still a key research field for thoracic surgical workers in China. Although China has a high incidence of esophageal cancer, > 90% of patients are diagnosed at a middle or late stage. As a result, the 5-year survival rate for Chinese esophageal cancer patients had no obvious decline over the past decades. In patients with early esophageal cancer who have undergone surgical or minimally invasive endoscopic treatment, the 5-year survival rate can reach > 90%. Therefore, early diagnosis is very important for its prognosis. Clarifying the molecular mechanisms underlying the development and progression of esophageal cancer and identifying biological markers for screening high-risk populations are therefore of great clinical importance for early diagnosis. In the present study, we collected fetal esophageal tissues, esophageal cancer tissues, different degrees of precancerous lesions, and tumor-adjacent normal esophageal epithelial tissues from fetuses of different gestational age or esophageal cancer patients from a high risk area of esophageal cancer in China, and utilized the proteomic technology to analyze the differential protein expression profiles in the development and growth of fetal esophageal epithelium and the development and progression of esophageal cancer, with an aim to clarify the molecular mechanism of esophageal cancer development.

# MATERIALS AND METHODS

*Specimens*

Esophageal cancer specimens were collected from 91 patients who underwent surgery at the Yaocun Esophageal Cancer Hospital (Linzhou, Henan Province, China) from 2000 to 2005. All patients did not undergo either chemotherapy or radiotherapy. There were 51 men and 40 women, with a median age of 58 years (range, 35-78 years).

Tumor-adjacent normal esophageal mucosal epithelial tissues were collected under a microscope. A solitary lesion was considered only when the lesion was separated from other lesions by ≥ 1 cm of morphologically normal esophageal epithelium. Tumor-adjacent esophageal epithelium was regarded as normal regardless of whether it was completely or only partially normal.

Fetal esophageal tissue specimens were collected from 65 fetuses (30 males and 35 females), and they had a gestational age of 3 (*n* = 7), 4 (*n* = 13), 5 (*n* = 9), 6 (*n* = 10), 7 (*n* = 10), 8 (*n* = 10), or 9 (*n* = 6) months. All fetuses were legally aborted fetuses or fetuses induced with misoprostol in the Family Planning Service Center of Hui County (Henan Province, China). Their parents had no prior history of usage of special drugs. The age of fetuses was determined based on the date of the last menstrual period, the crown-heal length, and the morphology of the hand and foot[1].

*Equipment and reagents*

WK600 nitric oxide laser gas analyzer (Weck, United States), Voyager DE Pro MALDI-TOF mass spectrometer (Applied Biosystems, United States), and GS-800 Calibrated Densitometer (Bio-Rad, United States) were used. Mouse anti-PRX6 monoclonal antibody was purchased from Chemicon (United States); ABC kit was purchased from Vector Laboratories (United States); DAB substrate kit was purchased from Beijing Zhong Shan-Golden Bridge Biological Technology Co., LTD (China); and lyophilized bovine serum albumin was purchased from Sigma (United States).

*Proteomic analysis*

Proteomic analysis was performed based on the study flow chart presented in Figure 1.

**Solid-phase isoelectric focusing electrophoresis:** Following removal of cover film, dried immobilized pH gradient (IPG, pH 3-10) strips (17 cm long) were plated in a fixed-length strip holder with the gel side down. After dispelling the air, 2 mL of cover fluid (mineral oil) was applied to minimize evaporation. The holder was then covered and placed on the IPG electrode platform, and isoelectric focusing electrophoresis was performed according to the protocol described in Table III-1. After electrophoresis was completed, Milli-Q water-wetted filter paper was used to wipe the mineral oil, and the strips were placed in a rehydration tray with the gel side up. Eight milliliters of equilibrium buffer I consisting of 6 mol/L urea, 2% SDS, 0.375 mol/L Tris-HCl (pH 8.8), 20% glycerol and 2% DTT was then added. After shaking on a horizontal rotator at 15 rpm for 15 min, the strips were taken out and put into equilibrium buffer II consisting of 6 mol/L urea, 2% SDS, 0.375 mol/L Tris-HCl (pH 8.8), 20% glycerol and 2.5% iodoacetamide for 15 min. The strips were finally dried and used for the second dimension electrophoresis.

**Sodium dodecyl sulfate-polyacrylamide gel electrophoresis:** Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using Tris-glycine-SDS buffer (5 ×: Tris 15.1 g, glycine 94 g, and SDS 5 g, dissolved in 1000 mL Milli-Q water). SDS-PAGE gels were prepared according to Table III-2. The gel was poured and allowed to polymerize. Pre-stained protein markers (10-15 μL) were spotted on 0.25 cm2 Whatman filter paper (3 mm), which was subsequently placed on the “+” end of the IPG strip. IPG strips were then imbedded in the second dimension and sealed using 0.5% agarose sealing solution (low melting-point agarose 0.5 g and 10 μL 1% bromophenol blue, dissolved in 100 mL 1 × electrophoresis buffer). Electrophoresis was carried out at a constant current of 10 mA per gel for 30 min, which was then raised to 40 mA. After electrophoresis was completed, gels were removed and stained.

**Silver nitrate staining and coomassie blue staining:** Silver nitrate staining was performed as described previously[35]. For Coomassie blue staining, SDS-PAGE gels were placed in Coomassie blue solution (Coomassie blue R-250 1.16 g, absolute ethanol 500 mL, and glacial acetic acid 100 mL, dissovled in1000 mL Milli-Q water) and incubated at room temperature for 2 h. The gels were then put into destaing solution (30% absolute ethanol and 10% glacial acetic acid) until the backgroud staining was removed.

**Image scanning and analysis:** StainedSDS-PAGE gels were scanned using a GS-800 calibrated densitometer at an optical resolution of 300 DPI and pixel of 8 bits. Images were analyzed with PDQuest 7.1.1 software. Image analysis included detecting spots on gels, editing spot and editing match, and correction of molecular weight (Mr) and isoelectric point (pI) of protein spots.

**Tryptic digestion of in-gel proteins:** For2-D gels used for mass spectrometry (MS) analysis, the loading amount of protein was raised to 1 mg. 2-D gel eclectrophoresis was performed as described above. To ensure the integrity and purity of protein spots, protein spots were cut and subjected to tryptic digesion in 2 weeks after staining[43].

**MALDI-TOF-MS analysis:** MALDI-TOF-MS analysis of tryptic digested fragments was performed by the Mass Spectrometry Laboratory of Shanghai Jikang Biochemical Technology Co., Ltd (Shanghai, China). Briefly, α-cyano-4-hydroxycinnamic acid was dissolved in 50% acetonitrile containing 0.1% trifluoroacetic acid to prepare a saturated solution, and 1 μL of the solution was mixed with 1 μL of tryptic digested fragments. The mixture (1 μL) was loaded onto the mass spectrometer. Positive-ion mass spectra were measured. Two peaks of self-digested trypsin (842.51 and 2211.1046) were used as internal standards.

*Immunohistochemistry*

The avidin-biotin- horseradish peroxidase complex (ABC) method was used. Briefly, paraffin embedded sections were dewaxed, rehydrated through graded ethanol solutions, and washed three times with PBS. After endogenous peroxidase activity was blocked with 0.3% H2O2, sections were incubated with normal horse/goat serum (1:50) for 20 min, followed by incubation with a primary antibody diluted with 2% BSA (sPLA2, 1:200; PRX6, 1:500) at 4 °C overnight. Sections were then incubated with a secondary antibody diluted with 2% BSA (1:200) for 45 min and ABC (1:1:50) for 30 min at room temperature. Following DAB coloration, sections were counterstained with hematoxylin for 15-30 s and mounted. A negative control was run by replacing the primary antibody with PBS, and p53-positive esophageal cancer tissue was used as a positive control. Staining intensity was scored as follows: 0 (no staining); 1 (light yellow granules on the membrane or in the cytoplasm); 2 (yellow granules); 3 (brown granules). Five hundred cells were counted in five microscopic fields per slide to calculate the percentage of stained cells, which was scored as follows: 0 (< 5%); 1 (5%-25%); 2 (25%-75%); 3 (> 75%). Negative, positive and strongly positive staining was considered when the sum of the score of staining intensity score and the score of the percentage of stained cells was 0, 1-4, and > 4, respectively.

*Quality control*

Differential protein spots that were present on 2-D gels for esophageal cancer and fetal esophageal tissues but not on gels for normal esophageal epithelial tissues were chosen for further analysis. To ensure the reproduciblity of 2-D gel electrophresis, 2-D gel electrophresis for each sample was repeated at least twice.

*Statistical analysis*

Statistical analyses were performed using SPSS10.0 software. Kruskal-Wallis and Mann-Whitney tests were used for comparing intergroup differences, with statistical significance set at ɑ = 0.05.

# RESULTS

*Selection of landmark protein spots on 2-D gel images*

By comparing differnt 2-D gel images for different samples, four landmark protein spots (A-D) that were present on all gel images were selected (Figures 2 and 3). Comparison of these spots with protein markers showed that their Mr was 40.2 KD, 14.2 KD, 16.8 KD and 28 KD, respectively, and PDQuest7.1.1 software determined their PI as 5.9, 7.1, 3.4 and 4.2, respectively.

*Peptide mass fingerprint analysis and search of protein databases*

Protein spots that were signficantly differntially expressed on 2-D gel images were cut and then subjected to in-gel tryptic digestion and MALDI-TOF analysis to obtain the Peptide mass fingerprint (PMF). PMF analysis and search of protein databases were then performed to identify differentially expressed portein spots. Table 1 lists the name of proteins, their theoretical and observed pI and Mr, number of matched peptide fragments, sequence coverage and MOWSE score. When searching protein databases, we strictly restricted the above parameters to improve the accuracy of database search. After PMF analysis and search of protein databases, a total of 21 differential proteins were identified, of which some represent a protein isoform.

*Immunohistochemical staining for peroxiredoxin 6 (PRX6)*

PRX6 protein was stained brown and mainly localized on the membrane, occasionally in the cytoplasm and nucleus (Figure 4).

In morphologically normal adult esophageal epithelial tissues, moderate staining of PRX6 protein was observed. With the progression of esophageal lesions, the positive rate of PRX6 protein expression showed a declining trend, especially prominent in dysplasia (DYS) and carcinoma in situ (CIS) (Figure 1), in which weak staining of PRX6 protein predominated. In tumor-adjacent esophageal epithelial tissues, the rate of strongly positive staining (≥ 4 points) decreased from 43% in normal epithelium (NOR) to 35% in basal cell hyperplasia (BCH). In DYS, moderately or weakly positive staining of PRX6 protein (< 4 points) predominated. The majority of CIS lesions (79%) showed no staining for PRX6 protein, with weak staining predominating. Interestingly, cancer cells in SCC showed varying degrees of PRX6 staining, with strongly positive staining (≥4 points) predominating. In seven cases of well differentiated SCC, varying degrees of PRX6 staining were observed. With the decrease in the differentiation degree of SCC, PRX6 protein expression gradually declined (*P* < 0.05) (Table 2).

In fetal esophageal epithelial tissues, the positive rate of PRX6 protein was 87%. In esophageal epithelial tissues from fetuses at a gestational age of 4-6 mo, strongly positive staining of PRX6 protein (≥ 4 points) predominated. In esophageal epithelial tissues from fetuses at a gestational age of 3, 7 or 8 mo, moderately or weakly positive staining (< 4 points) predominated. In esophageal epithelial tissues from fetuses at a gestational age of 8 mo, both strongly positive staining and negative staining can be observed (Table 2). Statistical analysis showed that PRX6 protein expression in esophageal epithelial tissues from fetuses at a gestational age of 4 or 7 mo differed significantly compared with that from fetuses of other gestation age groups (*P* < 0.05).

# DISCUSSION

The development and progression of esophageal cancer are a multi-stage process involving many genes. Proteomics is the study of the entire set of proteins expressed by a single cell or tissue. With the aid of proteomics, changes in protein molecules directly related to tumor development and progression can be identified, thus allowing to find markers for early diagnosis of tumors and monitoring of curative effects. This study utilized the 2-DE based proteomic technology to identify differentially expressed proteins in fetal esophageal tissues, esophageal cancer tissues, and tumor-adjacent normal esophageal epithelial tissues from fetuses of different gestational age or esophageal cancer patients from a high risk area of esophageal cancer in China. As a result, a total of 21 significantly differentially expressed proteins were identified, which may be related to the development and growth of fetal esophageal epithelium or the development and progression of esophageal cancer.

PRX6 protein belongs to the antioxidant peroxiredoxin family, which is ubiquitously expressed in prokaryotes and eukaryotes[11] and has six mammalian members. Mireille Chevallet *et al*[12] found that PRX6 expression continued to rise within 1-24 h after oxidative stress. Besides antioxidant properties, peroxiredoxins can also be radiation protective, stimulate cell proliferation, and participate in cell signal transduction. This study found that PRX6 expression was elevated in esophageal cancer tissues where cell metabolism and proliferation are active, suggesting that increased PRX6 may inhibit the excessive production of reactive oxygen species and maintain cell homeostasis to protect cells from damage. Similar to our results, PRX protein expression was also found to be elevated in malignant mesothelioma, lung cancer, and oral cancer[13]. In our previous proteomic study of esophageal squamous cell carcinoma, PRX1 protein expression was found to be up-regulated, but PRX2 protein expression was down-regulated[14], indicating that the development and progression of esophageal squamous cell carcinoma involves the changes in a variety of antioxidant proteins, and different antioxidant proteins or protein isoforms may have different functions in the development and progression of esophageal cancer. Further studies should be performed to clarify the exact mechanisms of these antioxidant proteins.

The most important finding of this study is that the expression of PRX6 protein decreased with the progression of esophageal lesions. In tumor-adjacent normal esophageal epithelial tissues, PRX6 protein was highly expressed; however, PRX6 protein expression was significantly reduced in CIS. PRX6 protein expression was positively correlated with the degree of tumor differentiation in esophageal squamous cell cancer. With the decrease in tumor differentiation, PRX6 protein expression decreased. In the fetal esophageal epithelium, PRX6 protein expression showed a fluctuating pattern with the increase of gestational age. The intensity of PRX6 protein expression was positively correlated with the degree of differentiation of epithelial cells. PRX6 protein expression was highly expressed in well differentiated epithelial cells, but lowly expressed or not expressed in lowly differentiated epithelial cells.

Both fetal esophageal epithelium and carcinoma tissues have active cell proliferation and metabolism, which may result in increased peroxide generation. PRX6 protein in fetal esophageal epithelium and carcinoma tissues may have antioxidant effects by eliminating peroxides produced by the cell metabolism, thus protecting cells from damage. Loss of expression of PRX6 protein in CIS may promote cell proliferation and facilitate the progression of precancerous lesions. However, the dynamic expression pattern of PRX6 protein in esophageal precancerous lesions and fetal esophageal epithelium suggests that PRX6 protein is associated with the multistage evolution of esophageal cancer and may inhibit cell proliferation and promote the differentiation of esophageal epithelial cells. Loss of expression of PRX6 protein in CIS is likely to promote cell proliferation and facilitate the progression of precancerous lesions. In poorly differentiated carcinoma tissue, loss of PRX6 protein may lead to rapid cell proliferation. Under certain conditions, PRX6 protein may also be involved in the induction of differentiation of cancer cells, thus resulting in the formation of highly differentiated carcinoma tissue. In fetal esophageal epithelium, PRX6 protein expression showed no significant correlation with gestational age, but was, to some extent, associated with the morphology of epithelial cells. In the base layer where cells are arranged neatly, the level of PRX6 protein expression was high. In contrast, when the arrangement of epithelial cells was disorderly, PRX6 protein exhibited low expression. These findings suggest that PRX6 protein may play an important role in the process of differentiation of fetal esophageal epithelial cells. We speculate that PRX6 protein may promote the trans-differentiation from precancerous lesions to normal esophageal epithelium. However, the precise role of PRX6 protein in cell differentiation requires further research.

This study utilized the 2-DE based proteomic technology to analyze the differential protein expression profiles in fetal esophageal tissues, esophageal cancer tissues, and tumor-adjacent normal esophageal epithelial tissues from fetuses of different gestational age or esophageal cancer patients from a high risk area of esophageal cancer in China, and identified 21 significantly differentially expressed proteins that may be related to the development and growth of fetal esophageal epithelium or the development and progression of esophageal cancer, such as Dermatonontin, S100A9, HSP27, and PRX6. Our results suggest that the development and progression of esophageal cancer are a result of interactions of many genetic changes (accumulation or superposition). These proteins are related not only to esophageal cancer, but also to other tumors. The identification of proteins associated with esophageal cancer and fetal esophageal development can improve the understanding of the molecular mechanism of esophageal cancer development and may help provide a fetal esophageal model for esophageal cancer. PRX6 protein plays an important role in the induction of differentiation of esophageal epithelial cells, and PRX6 protein expression level may be used as an important marker for evaluating cell differentiation. In this regard, further research of molecular mechanism of PRX6 is of great significance.

**COMMENTS**

***Background***

The fetal esophageal epithelium is developed from unmatured monolayer columnar epithelium gradually into a matured stratified squamous epithelium, differentiated from immature gradually to mature, epithelial cells differentiated from the active division and proliferation epithelial stem cells gradually matured into stratified squamous epithelium; The adult esophageal epithelial carcinogenesis is the differentiation of mature epithelial tissue in the role of carcinogenic factors, the emergence of hyperplasia and abnormal differentiation eventually developed into cancer. Obviously, the two have the opposite differentiation process. To find the protein molecules that are differentially or identically expressed in the process of maturation and differentiation of fetal esophageal epithelium and carcinogenesis of adult esophageal epithelium, to strengthen the understanding of molecular mechanism of esophageal carcinogenesis, so as to provide an important theoretical basis for the screening and detection of early molecular markers in high-risk population.

***Research frontiers***

Clarifying the molecular mechanisms underlying the development and progression of esophageal cancer and identifying biological markers for screening high-risk populations are therefore of great clinical importance for early diagnosis. Autilized the proteomic technology to analyze the differential protein expression profiles in the development and growth of fetal esophageal epithelium and the development and progression of esophageal cancer, with an aim to clarify the molecular mechanism of esophageal cancer development.

***Innovations and breakthroughs***

The authors identified 21 differentially expressed proteins by PMF and database analysis in the study, and some proteins contained different isoforms.

***Applications***

PRX6 protein expression level may be used as an important marker for evaluating cell differentiation. In this regard, further research of molecular mechanism of PRX6 is of great significance.

***Terminology***

MALDI-TOF-MS:Matrix-assisted laser desorption/ Ionization time of flight mass spectrometry.

***Peer-review***

This is an excellent study. In this study, the authors analyzed the differential protein expression profiles in fetal.

**REFERENCES**

1 **Sheng KL,** Zhu SY, Liu YS. Observation of human fetal eosphageal epihtelium. *Acta Anat Sin* 1999; **30**: 158-160 [DOI: 10.16098/j.issn.0529-1356.1999.02.017]

2 **Superti-Furga A**, Rocchi M, Schäfer BW, Gitzelmann R. Complementary DNA sequence and chromosomal mapping of a human proteoglycan-binding cell-adhesion protein (dermatopontin). *Genomics* 1993; **17**: 463-467 [PMID: 8104875 DOI: 10.1006/geno.1993.1348]

3 **Catherino WH**, Leppert PC, Stenmark MH, Payson M, Potlog-Nahari C, Nieman LK, Segars JH. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. *Genes Chromosomes Cancer* 2004; **40**: 204-217 [PMID: 15139000 DOI: 10.1002/gcc.20035]

4 **Takeuchi T,** Suzuki M, Kumagai J, Kamijo T, Sakai M, Kitamura T. Extracellular matrix Dermatopontin modulates prostate cell growth in vivo. *J Endocrinol* 2006; **190**: 351-361 [MID: 16899568 DOI: 10.1677/joe.1.06619]

5 **Tsibris JC**, Segars J, Coppola D, Mane S, Wilbanks GD, O'Brien WF, Spellacy WN. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. *Fertil Steril* 2002; **78**: 114-121 [PMID: 12095500]

6 **Donato R**. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. *Int J Biochem Cell Biol* 2001; **33**: 637-668 [PMID: 11390274]

7 **Stulík J**, Osterreicher J, Koupilová K, Knízek A, Bures J, Jandík P, Langr F, Dedic K, Jungblut PR. The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. *Electrophoresis* 1999; **20**: 1047-1054 [PMID: 10344284 DOI: 10.1002/(SICI)1522-2683(19990101)20]

8 **Jungblut PR**, Zimny-Arndt U, Zeindl-Eberhart E, Stulik J, Koupilova K, Pleissner KP, Otto A, Müller EC, Sokolowska-Köhler W, Grabher G, Stöffler G. Proteomics in human disease: cancer, heart and infectious diseases. *Electrophoresis* 1999; **20**: 2100-2110 [PMID: 10451122 DOI: 10.1002/(SICI)1522-2683(19990701)20]

9 **Ott HW**, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C, Illmensee K. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. *Cancer Res* 2003; **63**: 7507-7514 [PMID: 14612552]

10 **Arai K**, Teratani T, Nozawa R, Yamada T. Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. *Oncol Rep* 2001; **8**: 591-596 [PMID: 11295086]

11 **Rhee SG**, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. *IUBMB Life* 2001; **52**: 35-41 [PMID: 11795591 DOI: 10.1080/15216540252774748]

12 **Susin SA**, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M, Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. *J Exp Med* 1996; **184**: 1331-1341 [PMID: 8879205]

13 **Kinnula VL**, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. *J Pathol* 2002; **196**: 316-323 [PMID: 11857495 DOI: 10.1002/path.1042]

14 **Qi Y**, Chiu JF, Wang L, Kwong DL, He QY. Comparative proteomic analysis of esophageal squamous cell carcinoma. *Proteomics* 2005; **5**: 2960-2971 [PMID: 15986332 DOI: 10.1002/pmic.200401175]

15 **Hartl FU**. Molecular chaperones in cellular protein folding. *Nature* 1996; **381**: 571-579 [PMID: 8637592 DOI: 10.1038/381571a0]

16 **Aldrian S**, Trautinger F, Fröhlich I, Berger W, Micksche M, Kindas-Mügge I. Overexpression of Hsp27 affects the metastatic phenotype of human melanoma cells in vitro. *Cell Stress Chaperones* 2002; **7**: 177-185 [PMID: 12380685]

17 **Lemieux P**, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, Fuqua SA. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. *Invasion Metastasis* 1997; **17**: 113-123 [PMID: 9702938]

18 **Wang LD**, Qiu SL, Yang GR, Lipkin M, Newmark HL, Yang CS. A randomized double-blind intervention study on the effect of calcium supplementation on esophageal precancerous lesions in a high-risk population in China. *Cancer Epidemiol Biomarkers Prev* 1993; **2**: 71-78 [PMID: 8420615]

19 **Liang LY,** Wang WR, Guo YT, Lu J, Yang J, Jiang L. Determination of modification rate and content of PEGylated CN10 by RP-HPLC. *Weishengwuxue Mianyixue Jinzhan* 2015; **43**: 8-12 [DOI: 10.13309 /j.cnki.pmi.2015.01.002]

20 **Liu Y,** Yang HY. Recommendations from the Ad Hoc Committee of Experts on standardization of positive controls in diagnostic immunohistochemistry. *Linchuang Yu Shiyan Binglixue Zazhi* 2016; **32**: 1-3 [DOI: 10.13315/j.cnki.cjcep.2016.01.001]

21 **Zheng SW**, Lai D, Zhao SQ. Preparation and immunoassay of dibutyl phthalate artificial antigens. *Huanan Nongye Daxue Xuebao* 2016; **37**: 107-112 [DOI: 10.7671/j.issn.1001-411X.2016.02.017]

**P-Reviewer:** AndersenV, Kruis W, Sato H, Yamaoka Y **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): A, A, A


Grade B (Very good): 0

Grade C (Good): C




Grade D (Fair): 0

Grade E (Poor): 0


 **Figure 1** **Flow chart of proteomic analysis.**




**Figure 2** **2-D gel images for tumor-adjacent normal esophageal epithelial tissue, esophageal squamous cell carcinoma tissue, and fetal esophageal tissue.**



**Figure 3** **A typical differential protein spot in tumor-adjacent normal esophageal epithelial tissue, esophageal squamous cell carcinoma tissue, and fetal esophageal tissue.** The spot was rarely detected in normal esophageal epithelial tissue, but was overexpressed in esophageal squamous cell carcinoma and fetal esophageal tissues.



**Figure 4** **Expression of PRX6 expression in esophageal tissues from fetuses at a gestational age of 3-8 mo (DAB, × 200).**



**Figure 5** **Expression of PRX6 expression in esophageal tissues from fetuses at a gestational age of 3-8 mo (DAB, × 200).**

**Table 1 Identification of differentially expressed proteins in tumor-adjacent normal esophageal epithelial tissue, esophageal squamous cell carcinoma tissue, and fetal esophageal tissue**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Sport** | **Protein name and theoretical pI and Mr** | **Observed pI and Mr** | **No. of matched peptide fragments** | **Sequence coverage** | **MOWSE score** |
| 2 | USP30 6.87/45546 | 9.3/32 | 2 | 4 | 21 |
| 4 | Thyroid hormone receptor interactor 4.56/11 8489 | 7.8/31 | 3 | 56 | 51 |
| 5 | Cardiac muscle 5.34/22563 | 6.25/29 | 5 | 24 | 66 |
| 6 | Chain A, crystal structure of a recombinant glutathione transferase 5.09/23202 | 6.2/24 | 5 | 43 | 85 |
| 7 | Dermatopontin precursor 4.7/23989 | 5.3/21.5 | 5 | 29 | 82 |
| 10 | Heat shock protein 27 7.83/22313 | 7.1/20.5 | 5 | 29 | 79 |
| 11 | S100 calcium-binding protein A9 5.71/13234 | 6.3/15 | 5 | 40 | 74 |
| 12 | G-gamma-hemoglobin 6.17/11033 | 7.5/16 | 3 | 45 | 65 |
| 13 | MB protein 9.24/10863 | 8.4/15.5 | 3 | 32 | 65 |
| 14 | Immunoglobulin heavy chain variable region 9.78/13026 | 8.6/14 | 3 | 34 | 70 |
| 15 | PREDICTED: hypothetical protein 5.27/6706 | 8.1/12 | 2 | 44 | 52 |
| 16 | Immunoglobulin heavy chain variable region 9.04/13053 | 7.1/11 | 2 | 26 | 49 |
| 17 | Heat shock 27kDa protein 1 5.98/22768 | 9.2/16 | 6 | 33 | 80 |
| 18 | hCG1659706 10.28/5287 | 9.5/21 | 2 | 64 | 37 |
| 19 | Smooth muscle protein 8.56/22461 | 9.4/19 | 6 | 26 | 86 |
| 21 | hCG1997574 9.07/29453 | 7.3/32 | 7 | 31 | 93 |
| 22 | Heat shock 27kDa protein 1 5.98/22768 | 6.8/32 | 6 | 35 | 84 |
| 23 | Disabled homolog 1 (Drosophila) 9.40/22903 | 7.15/31 | 6 | 26 | 66 |
| 24 | Phosphoglycerate mutase 1 (brain), 6.40/24669 | 7.3/31 | 8 | 40 | 117 |
| 25 | Peroxiredoxin 6 6.00/25019 | 7.1/27.8 | 8 | 41 | 116 |
| 26 | Chain A, human triosephosphate isomerase of new crystal form 6.50/26666 | 7.3/30 | 10 | 38 | 160 |

**Table 2** **Expression of PRX6 protein in different types of esophageal lesions *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **TISSUE** | **PRX6** | | | |
| **No. of cases** | **Negative** |  | **Positive** | |
|  |  | |
| Tumor-adjacent |  |  |  | |
| NOR | 37 | 3 (8) | 34 (92) | |
| BCH | 37 | 3 (8) | 34 (92) | |
| DYS | 29 | 18 (62) | 11 (38) | |
| CIS | 28 | 22 (79) | 6 (21) | |
| Esophageal cancer |  |  |  | |
| W-SCC | 7 | 0 | 7 (100) | |
| M-SCC | 16 | 3 (19) | 13 (81) | |
| P-SCC | 6 | 5 (83) | 1 (17) | |

*P* < 0.05, NOR *vs* DYS, CIS, M-SCC or P-SCC; BCH *vs* CIS, DYS, M-SCC or P-SCC; DYS *vs* W-SCC or M-SCC; CIS *vs* W-SCC or M-SCC; P-SCC *vs* W-SCC or M-SCC.

**Table 3 Expression of PRX6 expression in esophageal tissues from fetuses of different gestational age *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Age (mo)** | **PRX6** | | | |
| **No. of cases** | **Negative** |  | **Positive** | |
| 3 | 6 | 0 | 6 (100) | |
| 4 | 4 | 0 | 4 (100) | |
| 5 | 6 | 1 (17) | 5 (83) | |
| 6 | 6 | 0 | 6 (100) | |
| 7 | 5 | 1 (20) | 4 (80) | |
| 8 | 6 | 1 (17) | 5 (83) | |
| 9 | 6 | 2 (33) | 4 (67) | |

*P* < 0.05, 3 mo *vs* 4 mo, 4 mo *vs* 7 mo, or 6 mo *vs* 7 mo.